Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Genetic downregulation of Dnm2 as a therapeutic approach in a murine model of X-linked myotubular myopathy (Mtm1-/y)

ABSTRACT: Genetic downregulation of Dnm2 as a therapeutic approach in a murine model of X-linked myotubular myopathy (Mtm1-/y)

PROVIDER: PRJNA671746 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR12893519.fastq.gz	Fastqsanger.gz
	SRR12893520.fastq.gz	Fastqsanger.gz
	SRR12893521.fastq.gz	Fastqsanger.gz
	SRR12893522.fastq.gz	Fastqsanger.gz
	SRR12893523.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 45

Similar Datasets

Genetic downregulation of Dnm2 as a therapeutic approach in a murine model of X-linked myotubular myopathy (Mtm1-/y)

Project description:In this study, we performed RNA sequencing on tibialis anterior muscle of male mice. WT and Mtm1 deficient (Mtm1-/y) mice as well as on Dnm2+/- mice and on Mtm1-/y mice crossed with Dnm2+/- (Mtm1-/yDnm2+/-) were sequenced. A longitudinal follow up was established by sequencing all the genotypes at E18.5, 2w and 7w.

2020-12-15 | GSE160079 | GEO

Genetic downregulation of Dnm2 as a therapeutic approach in a murine model of X-linked myotubular myopathy (Mtm1-/y)

Project description:In this study, we performed mass spectometry on tibialis anterior muscle of male mice. WT and Mtm1 deficient (Mtm1-/y) mice as well as on Dnm2+/- mice and on Mtm1-/y mice crossed with Dnm2+/- (Mtm1-/yDnm2+/-) were analyzed. A longitudinal follow up was established by analyzing all the genotypes at E18.5, 2w and 7w.

2022-10-13 | PXD021725 | Pride

Natural history of a mouse model of X-linked myotubular myopathy

Project description:X-linked myotubular myopathy (XLMTM) is a severe monogenetic disorder of the skeletal muscle. It is caused by loss-of-expression/function mutations in the myotubularin (MTM1) gene. Much of what is known about the disease, as well as the treatment strategies, has been uncovered through experimentation in pre-clinical models, particularly the Mtm1 gene knockout mouse line (Mtm1 KO). Despite this understanding, and the identification of potential therapies, much remains to be understood about XLMTM disease pathomechanisms, and about the normal functions of MTM1 in muscle development. To lay the groundwork for addressing these knowledge gaps, we performed a natural history study of Mtm1 KO mice. This included longitudinal comparative analyses of motor phenotype, transcriptome and proteome profiles, muscle structure and targeted molecular pathways.We identified age-associated changes in gene expression, mitochondrial function, myofiber size and key molecular markers, including DNM2. Importantly, some molecular and histopathologic changes preceded overt phenotypic changes, while others, such as triad structural alternations, occurred coincidentally with the presence of severe weakness. In total, this study provides a comprehensive longitudinal evaluation of the murine XLMTM disease process, and thus provides a critical framework for future investigations.

2022-07-08 | GSE207447 | GEO

X-linked myotubular myopathy is associated with epigenetic alterations and is ameliorated by HDAC inhibition

Project description:X-linked myotubular myopathy (XLMTM) is a fatal neuromuscular disorder caused by loss of function mutations in MTM1 . At present, there are no directed therapies for XLMTM, and incomplete understanding of disease pathomechanisms. To address these knowledge gaps, we performed a drug screen in mtm1 mutant zebrafish andidentified four positive hits, including valproic acid, which functions as a potent suppressor of the mtm1 zebrafish phenotype via HDAC inhibition. We translated these findings to a mouse XLMTM model, and showed that valproic acid ameliorates the murine phenotype.

2022-08-08 | GSE210642 | GEO

Natural history of a mouse model of X-linked myotubular myopathy

Project description:Natural history of a mouse model of X-linked myotubular myopathy

| PRJNA855625 | ENA

Dnm2 downregulation by antisense oligonucleotide (ASO1) injections rescue a murine model of recessive centronuclear myopathy (Bin1mck-/-)

Project description:Dnm2 downregulation by antisense oligonucleotide (ASO1) injections rescue a murine model of recessive centronuclear myopathy (Bin1mck-/-)

| PRJNA671741 | ENA

Dnm2 downregulation by antisense oligonucleotide (ASO1) injections rescue a murine model of autosomal dominant centronuclear myopathy (Dnm2SL/+)

Project description:Dnm2 downregulation by antisense oligonucleotide (ASO1) injections rescue a murine model of autosomal dominant centronuclear myopathy (Dnm2SL/+)

| PRJNA671743 | ENA

Tamoxifen therapy in a murine model of myotubular myopathy (TAM4MTM)

Project description:Tamoxifen therapy in a murine model of myotubular myopathy (TAM4MTM)

| PRJNA492750 | ENA

Some DNM2 mutations cause extremely severe congenital myopathy and phenocopy myotubular myopathy.

Project description: Not available

| S-EPMC6134552 | biostudies-literature

Dnm2 downregulation by antisense oligonucleotide (ASO1) injections rescue a murine model of recessive centronuclear myopathy (Bin1mck-/-)

Project description:In this study, we performed RNA sequencing on tibialis anterior muscle of male mice. WT (injected with PBS) and Bin1mck-/- (injected with PBS) mice as well as ASO1 injected Bin1mck-/- mice and ASO1 injected WT mice were sequenced at 7 weeks of age. ASO1 targets specifically Dnm2 ARN.

2020-12-15 | GSE160077 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data